MXPA03003829A - Acidos alcanoicos substituidos. - Google Patents

Acidos alcanoicos substituidos.

Info

Publication number
MXPA03003829A
MXPA03003829A MXPA03003829A MXPA03003829A MXPA03003829A MX PA03003829 A MXPA03003829 A MX PA03003829A MX PA03003829 A MXPA03003829 A MX PA03003829A MX PA03003829 A MXPA03003829 A MX PA03003829A MX PA03003829 A MXPA03003829 A MX PA03003829A
Authority
MX
Mexico
Prior art keywords
secure transaction
transaction systems
systems
secure
transaction
Prior art date
Application number
MXPA03003829A
Other languages
English (en)
Inventor
Neil Victor Harris
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0027024A external-priority patent/GB0027024D0/en
Priority claimed from GB0124528A external-priority patent/GB0124528D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of MXPA03003829A publication Critical patent/MXPA03003829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MXPA03003829A 2000-11-04 2001-11-02 Acidos alcanoicos substituidos. MXPA03003829A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0027024A GB0027024D0 (en) 2000-11-04 2000-11-04 Substituted Phenyl-Cycloalkyl-Alkanoic acids compounds
US25617000P 2000-12-13 2000-12-13
GB0124528A GB0124528D0 (en) 2001-10-12 2001-10-12 Chemical compounds
US33559001P 2001-10-24 2001-10-24
PCT/GB2001/004864 WO2002036553A2 (en) 2000-11-04 2001-11-02 Substituted alkanoic acids

Publications (1)

Publication Number Publication Date
MXPA03003829A true MXPA03003829A (es) 2003-07-28

Family

ID=27447905

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003829A MXPA03003829A (es) 2000-11-04 2001-11-02 Acidos alcanoicos substituidos.

Country Status (6)

Country Link
US (1) US7166616B2 (es)
EP (1) EP1330432A2 (es)
JP (1) JP3786203B2 (es)
CA (1) CA2427750C (es)
MX (1) MXPA03003829A (es)
WO (1) WO2002036553A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003829A (es) 2000-11-04 2003-07-28 Aventis Pharma Ltd Acidos alcanoicos substituidos.
BRPI0317463B8 (pt) * 2002-12-19 2021-05-25 Scripps Research Inst composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
CA2566923A1 (en) * 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2008034016A2 (en) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
EP2755961A1 (en) 2011-09-16 2014-07-23 Pfizer Inc Solid forms of a transthyretin dissociation inhibitor
DE102012208530A1 (de) * 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
US10115268B2 (en) 2013-03-15 2018-10-30 Linq3 Technologies Llc Systems and methods for integrated game play at payment-enabled terminals
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
IL293592A (en) 2019-12-06 2022-08-01 Vertex Pharma Transduced tetrahydrofurans as sodium channel modulators
AU2022284886A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289991T1 (de) * 1997-12-23 2005-03-15 Aventis Pharma Ltd Substituierte beta-alaninen
WO1999054321A1 (en) * 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
CA2341677A1 (en) * 1998-08-26 2000-03-23 Aventis Pharma Limited Aza-bicycles which modulate the inhibition of cell adhesion
MXPA03003829A (es) 2000-11-04 2003-07-28 Aventis Pharma Ltd Acidos alcanoicos substituidos.

Also Published As

Publication number Publication date
WO2002036553A2 (en) 2002-05-10
JP3786203B2 (ja) 2006-06-14
WO2002036553A3 (en) 2003-03-13
EP1330432A2 (en) 2003-07-30
CA2427750C (en) 2011-01-04
CA2427750A1 (en) 2002-05-10
US20040006056A1 (en) 2004-01-08
US7166616B2 (en) 2007-01-23
JP2004521868A (ja) 2004-07-22

Similar Documents

Publication Publication Date Title
AU2001251701A1 (en) Secure transaction system
MXPA03004002A (es) Sistema de retorno de medios.
AU9457901A (en) Transaction signature
AU2001276885A1 (en) Credit system
AU7971201A (en) Solid-suspending systems
ZA200210206B (en) Expression system.
AU5871101A (en) Transaction system
ZA200309505B (en) A payment system.
MXPA03003829A (es) Acidos alcanoicos substituidos.
HUP0302122A3 (en) Financial transaction system
GB0127298D0 (en) Transaction system
AU2001284074A1 (en) Payment system
ZA200306209B (en) Transaction system.
GB0018161D0 (en) Identity systems
HK1050018A1 (en) Stable initiator system.
ZA200209009B (en) E-commerce payment systems.
AU2002217196A1 (en) Payment system
GB0007135D0 (en) Cryosugical systems
GB0019851D0 (en) System for property transactions
HK1045740A1 (en) E commerce system.
AU2001235936A1 (en) Integrated pointing device-smartcard transaction security system
AUPQ854300A0 (en) Payment systems improvements
ZA200108756B (en) Transaction conducting system.
GB0014680D0 (en) Secure payment system
ZA200108686B (en) Verification system.

Legal Events

Date Code Title Description
FG Grant or registration